The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
Open accessAbstract
Objective: Increased de novo fatty acid (FA) synthesis and cholesterol biosynthesis have been independently described in many tumour types, including hepatocellular carcinoma (HCC). Design: We investigated the functional contribution of fatty acid synthase (Fasn)-mediated de novo FA synthesis in a murine HCC model induced by loss of Pten and overexpression of c-Met (sgPten/c-Met) using liver-specific Fasn knockout mice. Expression arrays and lipidomic analysis were performed to characterise the global gene expression and lipid profiles, respectively, of sgPten/c-Met HCC from wild-type and Fasn knockout mice. Human HCC cell lines were used for in vitro studies. Results: Ablation of Fasn significantly delayed sgPten/c-Met-driven hepatocarcinogenesis in mice. However, eventually, HCC emerged in Fasn knockout mice. Comparative genomic and lipidomic analyses revealed the upregulation of genes involved in cholesterol biosynthesis, as well as decreased triglyceride levels and increased cholesterol esters, in HCC from these mice. Mechanistically, loss of Fasn promoted nuclear localisation and activation of sterol regulatory element binding protein 2 (Srebp2), which triggered cholesterogenesis. Blocking cholesterol synthesis via the dominant negative form of Srebp2 (dnSrebp2) completely prevented sgPten/c-Met-driven hepatocarcinogenesis in Fasn knockout mice. Similarly, silencing of FASN resulted in increased SREBP2 activation and hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase (HMGCR) expression in human HCC cell lines. Concomitant inhibition of FASN-mediated FA synthesis and HMGCR-driven cholesterol production was highly detrimental for HCC cell growth in culture. Conclusion: Our study uncovers a novel functional crosstalk between aberrant lipogenesis and cholesterol biosynthesis pathways in hepatocarcinogenesis, whose concomitant inhibition might represent a therapeutic option for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citation
Cited by
Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 983
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.019 · Cited by 643
Zuo, X., Chen, Z., Gao, W., Zhang, Y., Wang, J., Wang, J., Cao, M., Cai, J., Wu, J., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0839-x · Cited by 447
Self-citationLipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
Metadata
- Authors
- Che, L., Chi, W., Qiao, Y., Zhang, J., Song, X., Liu, Y., Li, L., Jia, J., Pilo, M. G., Wang, J., Cigliano, A., Ma, Z., Kuang, W., Tang, Z., Zhang, Z., Shui, G., Ribback, S., Dombrowski, F., Evert, M., Pascale, R. M., Cossu, C., Pes, G. M., Osborne, T. F., Calvisi, D. F., Chen, X., & Chen, L.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2019-04-06
- Volume
- 69
- Issue
- 1
- Pages
- 177-186
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2925521234
- Cited by
- 203
- References
- 3
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. https://app.cochat.ai/papers/10.1136/gutjnl-2018-317581
- The paper
- Che, L., Chi, W., Qiao, Y., Zhang, J., Song, X., Liu, Y., Li, L., Jia, J., Pilo, M. G., Wang, J., Cigliano, A., Ma, Z., Kuang, W., Tang, Z., Zhang, Z., Shui, G., Ribback, S., Dombrowski, F., Evert, M., . . . Chen, L. (2020). Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. https://doi.org/10.1136/gutjnl-2018-317581
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.